Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

ACER
Acer Therapeutics Inc
stock NASDAQ

At Close
3/27/2023 3:59:30 PM EDT
0.7440USD-0.800%(-0.0060)149,349
0.5840Bid   0.9120Ask   0.3280Spread IEX
Pre-market
3/24/2023 8:00:30 AM EDT
0.7601USD+1.347%(+0.0101)0
After-hours
3/23/2023 4:00:30 PM EDT
0.7999USD+1.125%(+0.0089)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsNews
Jan 27, 2022
08:30AM EST  Acer Therapeutics and Relief Therapeutics Announce Presentation   GlobeNewswire Inc
Dec 22, 2021
08:30AM EST  Acer Therapeutics to Participate in January 2022 Virtual Investor   GlobeNewswire Inc
Dec 9, 2021
09:47PM EST  Acer Therapeutics Announces ACER-801 IND Clearance For The Treatment Of Induced Vasomotor Symptoms   Benzinga
08:30AM EST  Acer Therapeutics Announces ACER-801 IND Clearance for the   GlobeNewswire Inc
Nov 24, 2021
04:22PM EST  Acer Therapeutics S-3 Shows Registration For $100M Mixed Securities Shelf Offering   Benzinga
Nov 22, 2021
05:59AM EST  A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street   Benzinga
Nov 19, 2021
05:03PM EST  Acer Therapeutics Q3 EPS $(0.23) Up From $(0.51) YoY   Benzinga
05:01PM EST  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2021 and provided an update on Acers recent corporate developments.   GlobeNewswire Inc
Oct 26, 2021
08:37AM EDT  Acer Therapeutics, Relief Therapeutics Announce Issuance Of U.S. Patent 11,154,521 Covering ACER-001 Formulation   Benzinga
08:30AM EDT  Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S   GlobeNewswire Inc
Oct 7, 2021
08:36AM EDT  Acer Therapeutics Receives Notice of Allowance Of Key U.S. Patent Application Covering ACER-001 Formulation   Benzinga
08:30AM EDT  Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent   GlobeNewswire Inc
Oct 6, 2021
02:35PM EDT  Mid-Afternoon Market Update: US Stocks Turn Positive; Hovnanian Enterprises Shares Slide   Benzinga
12:08PM EDT  Mid-Day Market Update: Dow Tumbles Over 300 Points; Acer Therapeutics Shares Jump   Benzinga
08:56AM EDT  Acer Therapeutics Inc. (ACER) and its collaboration partner, RELIEF THERAPEUTICS Holding SA announced the FDA has accepted for filing the New Drug Application (NDA) for ACER-001 for the treatment of patients with Urea Cycle Disorders. The FDA has assigned a PDUFA target action date of June 5, 2022.   RTTNews
08:40AM EDT  Acer, Relief Therapeutics Announce FDA Acceptance For Filing Of NDA For ACER-001 To Treat Urea Cycle Disorders   RTTNews
08:30AM EDT  Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance   GlobeNewswire Inc
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
05:47AM EDT  The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 5.35 A.M. EDT).   RTTNews
05:30AM EDT  Acer Therapeutics and Relief Therapeutics Announced FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders With PDUFA Target Action Date of June 5, 2022   Benzinga
Sep 6, 2021
08:00AM EDT  The Rosen Law Firm, P.A. announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of Acer Therapeutics Inc. common stock (NASDAQ:ACER):   GlobeNewswire Inc
Aug 30, 2021
08:30AM EDT  Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual   GlobeNewswire Inc
Aug 10, 2021
04:53PM EDT  Acer Therapeutics Q2 EPS $(0.23) Up From $(0.56) YoY   Benzinga
04:05PM EDT  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2021 and provided an update on the Companys recent corporate developments.   GlobeNewswire Inc
Aug 9, 2021
08:41AM EDT  Acer Therapeutics, Relief Therapeutics Announce Submission Of NDA To FDA For ACER-001 For Uea Cycle Disorders   RTTNews
08:31AM EDT  Acer Therapeutics And Relief Therapeutics Announce Submission Of A New Drug Application To The FDA For ACER-001 For Treatment Of Urea Cycle Disorders   Benzinga
08:30AM EDT  Acer Therapeutics and Relief Therapeutics Announce Submission of a   GlobeNewswire Inc
Jun 10, 2021
08:34AM EDT  Acer Therapeutics Plans Clinical Trial For EDSIVO Following Type B FDA Meeting   RTTNews
08:31AM EDT  Acer Therapeutics Plans Clinical Trial For EDSIVO (Celiprolol) Following Type B FDA Meeting   Benzinga
08:30AM EDT  Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial estimated to take approximately 3.5 years to complete once fully enrolled   GlobeNewswire Inc
May 25, 2021
08:32AM EDT  Acer Therapeutics Announces Outcome Of Pre-NDA Meeting With FDA; Plans NDA Submission For ACER-001 In Q3 2021   Benzinga
08:30AM EDT  Acer Therapeutics Plans NDA Submission for ACER-001 in Q3   GlobeNewswire Inc
May 17, 2021
04:12PM EDT  Acer Therapeutics Q1 EPS $(0.11) Up From $(0.49) YoY   Benzinga
04:01PM EDT  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2021 and provided an update on the Companys recent corporate developments.   GlobeNewswire Inc
Mar 29, 2021
08:30AM EDT  Acer Therapeutics to Participate in Needham Virtual Healthcare   GlobeNewswire Inc
Mar 25, 2021
04:05PM EDT  Notice of Settlement of Derivative Suits   GlobeNewswire Inc
Mar 22, 2021
08:44AM EDT  Relief, Acer Therapeutics Sign Collaboration Agreement For Development Of ACER-001   RTTNews
08:30AM EDT  Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights   GlobeNewswire Inc
08:30AM EDT  Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics   Benzinga
06:18AM EDT  Relief and Acer Therapeutics Signed Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of UCDs and MSUD; , Acer to Receive ~$10M Cash Payment   Benzinga
Mar 15, 2021
08:38AM EDT  What's Happening With ACER Stock, MGM Stock, XPEV Stock?   Benzinga
Mar 3, 2021
04:48PM EST  Acer Therapeutics S-1 Shows Registration For 4.038M Share Offering Via Lincoln Park Capital Fund   Benzinga
Mar 1, 2021
04:10PM EST  Acer Therapeutics Q4 EPS $(0.50) Up From $(0.51) YoY   Benzinga
04:05PM EST  Acer Therapeutics Reports Fourth Quarter and Full Year 2020   GlobeNewswire Inc
08:30AM EST  Acer Therapeutics to Participate in March Virtual Investor Conferences   GlobeNewswire Inc
Feb 11, 2021
08:30AM EST  Acer Therapeutics Announces Topline Results from its   GlobeNewswire Inc
Jan 25, 2021
08:44AM EST  BZ NOTE: Acer Press Release Highlights Earlier-Announced Option Agreement With Relief Therapeutics   Benzinga
08:39AM EST  UPDATE: Acer To Receive $1M Payment To Obtain Exclusivity And A $4M Loan From Relief; If Definitive Agreement Is Executed, Acer To Receive $15M In Cash, Relief To Pay Up To $20M In Development And Commercial Costs   Benzinga
08:38AM EST  Relief Therapeutics And Acer Therapeutics Sign Option Agreement For Exclusivity To Negotiate Collaboration And License Agreement For Worldwide Development + Commercialization Of ACER-001 For Treatment Of Urea Cycle Disorders And Maple Syrup Urine Disease   Benzinga
08:35AM EST  Acer to receive $1 million payment to obtain exclusivity and a $4 million loan from Relief   GlobeNewswire Inc
05:46AM EST  Relief Therapeutics, Acer Therapeutics Signed Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease; Acer to Receive $1M Payment to Obtain Exclusivity and $4M Loan From Relief   Benzinga
Dec 22, 2020
08:50AM EST  Acer Reports Full Enrollment Of Pivotal Bioequivalence Trial Of ACER-001 For Urea Cycle Disorders   RTTNews
08:33AM EST  Acer Therapeutics Announces Full Enrollment Of Pivotal Bioequivalence Trial Of ACER-001 For Urea Cycle Disorders   Benzinga
08:30AM EST  Acer Therapeutics Announces Full Enrollment of Pivotal   GlobeNewswire Inc
Dec 17, 2020
08:33AM EST  Acer Therapeutics Announces Publication Of Vascular Ehlers-Danlos Syndrome Patient Registry Data From Sweden   Benzinga
08:30AM EST  Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos   GlobeNewswire Inc
Nov 10, 2020
04:22PM EST  Acer Therapeutics Q3 EPS $(0.51) Up From $(0.52) YoY   Benzinga
04:05PM EST  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2020, and provided an update on the Companys recent corporate developments.   GlobeNewswire Inc
Oct 15, 2020
09:30AM EDT  SHAREHOLDER ALERT: Schubert Firm Investigating Possible Breaches of Fiduciary   PR Newswire
Oct 1, 2020
08:30AM EDT  Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital   GlobeNewswire Inc
Aug 25, 2020
09:00AM EDT  Acer Therapeutics to Virtually Present at Upcoming Investor   GlobeNewswire Inc
Aug 13, 2020
04:04PM EDT  Acer Therapeutics Q2 EPS $(0.56) Up From $(1.09) YoY   Benzinga
04:01PM EDT  Advanced expanded pipeline of clinical stage product candidates, including emetine for COVID-19 and ACER-001 for Urea Cycle Disorders   GlobeNewswire Inc
Jul 28, 2020
11:09AM EDT  Insider Buys Acer Therapeutics's Shares   Benzinga
Jul 27, 2020
09:15AM EDT  Acer Therapeutics Entered Securities Purchase Agreement For Sale And Issuance Of 244.998K Shares Of Common Stock   Benzinga
Jul 23, 2020
10:02AM EDT  Kehoe Law Firm, P.C. is investigating potential breaches of fiduciary duty claims involving certain officers and/or directors of Acer Therapeutics, Inc. (Acer or the Company) (NASDAQ: ACER).   GlobeNewswire Inc


Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC